Lundbeck to present bexicaserin's dual mode of action at European Epilepsy Congress
Lundbeck will present preclinical data on bexicaserin's dual mode of action at the European Epilepsy Congress. The data suggest broader antiseizure activity.
H. Lundbeck A/S is presenting preclinical data on its investigational drug bexicaserin at the European Epilepsy Congress (Eures). The presentation focuses on mechanistic insights into the drug's dual mode of action for treating epilepsy.
According to the research, bexicaserin increases inhibitory and decreases excitatory neuronal activity. This dual effect may potentially broaden its antiseizure activity across different seizure types, including focal, generalized motor, and absence seizures.
Preclinical models have demonstrated bexicaserin's efficacy in various epilepsy models. These findings support the theoretical basis for the drug's potential as a versatile epilepsy treatment.
The European Epilepsy Congress convenes experts in the field to discuss epilepsy research and treatment. Lundbeck's presentation offers further details on the company's drug development pipeline and its efforts to find new therapeutic options for epilepsy.